{"classes":[{"categories":[{"measurements":[{"comment":"Not available = Not estimable due to the low number of events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"163.00"},{"comment":"Not available = Not estimable due to the low number of events","groupId":"OG001","lowerLimit":"60.00","upperLimit":"NA","value":"337.00"},{"comment":"Not available = Not estimable due to the low number of events","groupId":"OG002","lowerLimit":"60.00","upperLimit":"NA","value":"163.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"18"}],"units":"Participants"}],"description":"DOR was defined as the number of days from the date of the first disease response (Complete, Unconfirmed Complete or Partial Response) until the date of progression, analyzed using Kaplan-Meier methods.","dispersionType":"95% Confidence Interval","groups":[{"description":"Romidepsin 14mg/m\\^2 by intravenous (IV) infusion on Days 1, 8, 15 of each 28-day cycle.","id":"OG000","title":"Phase 1: Cohort 2: Romidepsin 14mg/m^2"},{"description":"Romidepsin 14mg/m\\^2 by intravenous (IV) infusion on Days 1, 8, 15 of each 28-day cycle.","id":"OG001","title":"Phase 2: Romidepsin 14mg/m^2"},{"description":"Romidepsin 14mg/m\\^2 by intravenous (IV) infusion on Days 1, 8, 15 of each 28-day cycle.","id":"OG002","title":"Total: Romidepsin 14mg/m^2"}],"paramType":"MEDIAN","populationDescription":"Intent to treat population for participants with PTCL who received at least one dose of romidepsin and achieved a PR or better (CR, CRu or PR)","reportingStatus":"POSTED","timeFrame":"Median follow-up time was 100 days; up to the data cut-off of 28 July 2015","title":"Kaplan Meier Estimate of Duration of Response (DOR) for PTCL Responders Based on the Modified 2007 IWC as Assessed by the IER.","type":"SECONDARY","unitOfMeasure":"days"}